1021.1000 13.80 (1.37%)
NSE Jun 11, 2025 13:08 PM
Volume: 42,688
 

1021.10
1.37%
BOB Capital Markets Ltd.
Q2 revenue in line at Rs 6bn but EBITDA/PAT 3%/6% below our estimates due to higher opex and a product mix change
Number of FII/FPI investors increased from 92 to 105 in Mar 2025 qtr.
More from Alivus Life Sciences Ltd.
Recommended